Guided Therapeutics (GTHP) Operating Margin (2010 - 2025)
Guided Therapeutics' (GTHP) quarterly Operating Margin came in at 120.34% in Q4 2025, up 5327966.0% year-on-year from N/an in Q4 2024, and up 85.11% quarter-over-quarter from 808.33% in Q3 2025.
Guided Therapeutics (GTHP) Operating Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics has disclosed Operating Margin across 16 years of filings, most recently posting 120.34% for Q4 2025.
- Operating Margin for Q4 2025 came in at 120.34%, up 5327966.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 309.26% (up 2981931.0% YoY), and the FY2025 annual result was 309.26%, up 2980503.0% from the prior year.
- Operating Margin came in at 120.34% for Q4 2025 at Guided Therapeutics, up from 808.33% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 120.34% in Q4 2025 to a low of 53400.0% in Q4 2024.
- The 5-year median for Operating Margin is 3626.14% (2023), against an average of 11790.73%.
- Across the five-year window, Operating Margin slumped 5188438 bps in 2024 and surged 5327966 bps in 2025, its largest moves.
- Guided Therapeutics' Operating Margin stood at 725.0% in 2021, then sank by 5528 bps to 40800.0% in 2022, then soared by 96 bps to 1515.62% in 2023, then slumped by 3423 bps to 53400.0% in 2024, then jumped by 100 bps to 120.34% in 2025.
- The last three Operating Margin figures came in at 120.34% (Q4 2025), 808.33% (Q3 2025), and 652.14% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.17% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 19.94% |
| 10 | Guided Therapeutics | - | - | 458,000.00 | -120.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.34% |
| Sep 30, 2025 | -808.33% |
| Jun 30, 2025 | -652.14% |
| Dec 31, 2024 | -53,400.00% |
| Mar 31, 2024 | -5,983.33% |
| Dec 31, 2023 | -1,515.63% |
| Jun 30, 2023 | -3,420.45% |
| Mar 31, 2023 | -3,831.82% |
| Sep 30, 2022 | -40,800.00% |
| Jun 30, 2022 | -14,340.00% |
| Mar 31, 2022 | -8,860.00% |
| Dec 31, 2021 | -725.00% |
| Sep 30, 2021 | -2,563.16% |
| Jun 30, 2021 | -28,050.00% |
| Dec 31, 2020 | -1,152.00% |
| Sep 30, 2020 | -198.70% |
| Dec 31, 2019 | -1,031.25% |
| Sep 30, 2019 | -18,800.00% |
| Jun 30, 2019 | -32,700.00% |
| Mar 31, 2019 | -1,427.78% |